Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jul;26(7):751-2.
doi: 10.1038/cr.2016.79. Epub 2016 Jun 21.

Prevention of breast cancer by RANKL/RANK blockade

Lorenzo Galluzzi  1   2   3   4   5 , Aitziber Buqué  1   2   3   4   5 , Guido Kroemer  2   3   4   5   6   7   8
Affiliations
Comment

Prevention of breast cancer by RANKL/RANK blockade

Lorenzo Galluzzi et al. Cell Res. 2016 Jul.

Abstract

Robust genetic evidence in mice and humans indicates that RANK signaling plays a major role in mammary carcinogenesis driven by BRCA1/BRCA2 mutations. These findings may inaugurate a new era of breast cancer prevention, changing the life of millions of women worldwide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
RANKL/RANK signaling in breast cancer. Mammary carcinogenesis driven by BRCA1 mutations relies on autocrine or paracrine RANKL/RANK signaling in mammary progenitor cells. Breast cancers developing as a consequence of BRCA1 mutations also depend on progesterone signaling (knowing that progesterone derivatives also promote mammary carcinogenesis), most likely as a result of progesterone receptor-driven RANKL expression and consequent proliferation of mammary progenitor cells. The mechanisms linking the accumulation of genetic defects to carcinogenesis via the RANKL/RANK system, as well as the possible impact of RANKL/RANK signaling in the mammary epithelium on anticancer immunosurveillance remain to be determined.
See this image and copyright information in PMC

Comment on

  • RANKL/RANK control Brca1 mutation-.
    Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M, Kozieradzki I, Schramek D, Edokobi N, Hersl J, Sampson A, Odai-Afotey A, Lazaro C, Gonzalez-Suarez E, Pujana MA, Cimba F, Heyn H, Vidal E, Cruickshank J, Berman H, Sarao R, Ticevic M, Uribesalgo I, Tortola L, Rao S, Tan Y, Pfeiler G, Lee EY, Bago-Horvath Z, Kenner L, Popper H, Singer C, Khokha R, Jones LP, Penninger JM. Sigl V, et al. Cell Res. 2016 Jul;26(7):761-74. doi: 10.1038/cr.2016.69. Epub 2016 May 31. Cell Res. 2016. PMID: 27241552 Free PMC article.

References

    1. Bianchini G, Balko JM, Mayer IA, et al. Nat Rev Clin Oncol 2016. May 17. doi:10.1038/nrclinonc.2016.66 - PMC - PubMed
    1. Welch HG, Gorski DH, Albertsen PC. N Engl J Med 2015; 373:1685–1687. - PubMed
    1. Sigl V, Owusu-Boaitey K, Joshi PA, et al. Cell Res 2016; 26:761–774. - PMC - PubMed
    1. Lacey DL, Boyle WJ, Simonet WS, et al. Nat Rev Drug Discov 2012; 11:401–419. - PubMed
    1. Vacchelli E, Aranda F, Eggermont A, et al. Oncoimmunology 2014; 3:e 27048. - PubMed

Substances